This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): ZS9, sodium zirconium cyclosilicate, Lokelma
Description: ZS-9 is a crystallized zirconium silicate designed as a sorbent, acting specifically to trap potassium ions over other ions in the gastrointestinal tract. Preclinical studies have shown that ZS-9 has a binding capacity exceeding that of existing polymer-based resins.
AstraZeneca and ZS Pharma
In November 2015, AstraZeneca announced that it has entered into a definitive agreement to acquire ZS Pharma. The transaction will give AstraZeneca access to ZS-9 for the treatment of hyperkalaemia. The acquisition is structured as an all-cash tender offer for all outstanding shares of ZS Pharma common stock at a price of $90 per share, followed by a merger in which each remaining untendered share of ZS Pharma common stock would be converted into the same $90 cash per share consideration as in the tender offer.
Under the terms of the merger agreement, AstraZeneca will commence a tender offer to acquire all outstanding shares of ZS Pharmas common stock. The Board of Directors of ZS Pharma has unanimously approved the terms of the agreement. The transaction is not subject to a financing condition.
In December 2015, AstraZeneca announced the successful completion of the tender offer for all of the outstanding shares of ZS Pharma and the...See full deal structure in Biomedtracker
Additional information available to subscribers only: